UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5085535 ( State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | Delaware | | 81-5085535 | | --- | --- | ...

Landos Biopharma, Inc. (NASDAQ:LABP) Q3 2021 Earnings Conference Call November 15, 2021 8:00 AM ET Company Participants Becky Mosig - Director of Administration and Operations Chris Garabedian - Chairman of the Board Tim Mayleben - Interim President and Chief Executive Officer Conference Call Participants Chris Howerton - Jefferies Jessica Fye - J.P. Morgan Thomas Smith - SVB Leerink Prakhar Agrawal - Jones Trading Disclaimer*: This transcript is designed to be used alongside the freely available audio reco ...

(0) (0) (0) HANDOS B 2 O P H A R M A , COMPANY PRESENTATION | SEPTEMBER 2021 (@ o Forward Looking Statement Statements in this presentation about future expectations, plans and prospects for Landos Biopharma, Inc. (the "Company"), including statements about the Company's strategy, clinical development of the company's therapeutic candidates, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 81-5085535 | | --- | --- | | (Sta ...

(●) (●) (0) AND O.S T B 2 O P H A R M A , COMPANY PRESENTATION | JUNE 2021 (@ o Forward Looking Statement Statements in this presentation about future expectations, plans and prospects for Landos Biopharma, Inc. (the "Company"), including statements about the Company's strategy, clinical development of the company's therapeutic candidates, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", "a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5085535 (State or other jurisdict ...

For the transition period from ___________ to ___________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-39971 WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 81-5085535 | ...